Cancers | Free Full-Text | BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma | HTML
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma: Molecular Therapy
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
JCM | Free Full-Text | Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma | HTML
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect
Frontiers | Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions | Immunology
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma | Semantic Scholar
Frontiers | Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting | Immunology
Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy
Phase I AMG 701 - Capsule Summary Slidesets - Myeloma - 2020 ASH Annual Meeting - Oncology - Clinical Care Options
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma | Leukemia
Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma - eBioMedicine
Frontiers | Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions | Immunology
BCMA Emerges as Hot Target in Myeloma, With CARs Leading the Way
Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma | Military Medical Research | Full Text
Summary clinical study results of anti-BCMA ADC, BiTE, and bispecific... | Download Scientific Diagram
Cancers | Free Full-Text | The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond | HTML
CD269 (BCMA) Antibody, anti-human, REAfinity™ | Recombinant antibodies | MACS Antibodies | Products | Miltenyi Biotec | Suomi
Clinical trials of anti-BCMA antibody-drug conjugates in RRMM. | Download Scientific Diagram
Mechanisms of action of anti-BCMA mAb, antibody drug conjugates and... | Download Scientific Diagram
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond | Journal of Hematology & Oncology | Full Text
Pregene Partners With CellPoint To Develop Anti-BCMA CAR-T Cell Therapy | Contract Pharma
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma | NEJM
Targeting B-cell maturation antigen in multiple myeloma | Immunotherapy
Clinical trials of anti-BCMA antibody-drug conjugates in RRMM. | Download Scientific Diagram
Multiple myeloma treatment: Anti-BCMA biologics to net $10 billion by 2027
CNCR Research: BCMA and Multiple Myeloma
BCMA targeted therapy! GSK antibody drug conjugates apply for sale at the end of the year – Creative Biolabs ADC Blog
